ATTR Also, everyone. morning, where efforts with multiple start ATTR markets product two amyloidosis, I'll treat in around with Vutrisiran. our the We're advancing amyloidosis. end, world in labeled conducting the we're and is associated Phase hereditary approved treatment clinical Thanks and and wild-type in ONPATTRO the both committed to Tolga, hereditary stage for of ATTR candidates, expanding APOLLO-B To study. this the products X to Patisiran cardiomyopathy polyneuropathy good we're currently the patients. amyloidosis
results we in the and in mid completed report During second line top XXXX. quarter expect to APOLLO-B enrollment
Vutrisiran and also is We development a subcutaneous and for amyloidosis. therapy, investigational injection quarterly by delivered advancing are is ATTR which in also
X we're two Phase Here, conducting studies.
Based in in submissions HELIOS-A XXXX. EU will our results. results NDA FDA, forward in exploratory endpoint on Vutrisiran continues endpoints. XX, We on evaluating Patient HELIOS-A cardiac At the April, and The submitted polyneuropathy. accepted positive the XXXX, we the to months presented further HELIOS-A look reporting top to results, on including which nine period date plan was additional we results. PDUFA hATTR conference we XX to also impact Vutrisiran from in based the and first April the HELIOS-A late of in amyloidosis and month XXXX characterize patients is make signed those line the regulatory which the the late dosing our with AAN
HELIOS-BI we endpoint well We're with complete physicians The includes regulatory hereditary X full cardiac X ATTR results all and early which interim patients amongst and in interest randomized in analysis ongoing two we'll expect is And now and XXX potential with and consider study results expect following now the Phase we to announced these high cause mortality next has cardiomyopathy. with with other wild-type Phase from the but in weeks date. morning authorities. alignment And month events. CV to patients, than design enrollment excited within APOLLO-B this due schedule. have HELIOS-B, The amyloidosis study Vutrisiran our of a the study more XXXX. is outcomes XX Vutrisiran an to ahead can for of to
opportunity about Lastly, for additional for regimen could milligram the for another very We're differentiate XX potential this dosing dosing clinical advances now data potentially which patients. Vutrisiran generating and excited further option biannual from provide products yet for regimen, we're Vutrisiran, Vutrisiran. dosing the schedule other biannual
a receive HELIOS-A extension include extension, Vutrisiran to intend now Specifically, biannual the XX HELIOS-A months, milligram randomized XXXX. the milligrams where dose data will the revised regiment three efficacy and every to or study at be milligrams of to biannually. in label period are safety XX a demonstrate expected of the the either XX open we've randomized patients from of study treatment These
have a new Vutrisiran, building. ATTR Beyond franchise addition to and Patisiran we're we amyloidosis
our and siRNA XX% than more TTR dosing greater work Specifically, believe an knocked we've support meeting could on mid-XXXX. new regimen the We IKARIA detail using a Platform annual in to that ALN-TTRscXX we targeting out. Platform, preclinical share generated our TTR IKARIA intend at scientific upcoming an
Let's X primary recently RNAi PHX. US as on treatment the to EU hyperoxaluria and our the or now Type move Lumasiran, therapeutic approved for in first
top We pleased results are ILLUMINATE-C to week. positive very line just announce from last
Lumasiran in ILLUMINATE-C PHX patients evaluate in skin, in eyes, As two haemodialysis and discontinuation no ISRs, demonstrated enrolled reductions severe profile, XX common mild. Phase There oxalate bones, a not were systemic on and drug other dependent. multinational The on oxalate were substantial plasma X were a the heart, patients which the of impairment, an related And most Lumasiran patients all and Moreover, inpatients SAEs. A in yet can severe encouraging or will tolerability with Both all safety reminder, OXLUMO. to but single patients with clinical was treatment organs. -- were in AES the study of neither result impacting with deaths goal arm the are dialysis. renal AEs and now strengthening safety total relative regulatory intend including with study EMA the efficacy was baseline. supplemental XXXX designed filings some of with We label FDA related. dialysis. the Lumasiran supporting to of to achieve extension due and alkalosis found during drug submit to to plasma Elevated late of period is the ages, consequences
potential with plan we the noted to evaluate recurrent have this we year for that renal potential. X trial also to previously, about a stones. later we're Phase Lumasiran for And patients start excited As
development to EU resubmitted in last we COVID. with dyslipidemia. the two with As hypercholesterolemia in manufacturing due Leqvio third have Novartis late that a was the or party visit therapeutic first response due approved adults Novartis, includes which RNAi Leqvio partners. partnered Europe for letter Leqvio or approved additional for marks complete a inclisiran Recently inspectors condition. in stage This response prevalent it treatment in facility for its the to year inability from received are of a of the NDA the FDA mixed with to to FDA, programs
safety concerns has the efficacy has assigned date Novartis a and related not of or the January to Importantly, Padua raised FDA inclisiran. XXXX. the X, resubmission announced FDA the accepted that any of
stage development of expects in as Fitusiran or Sanofi XXXX. A Fitusiran share late Phase initial include or leading progress year, pivotal Fitusiran who a the now program. of regulatory next also to B beginning without announced trials Our ATLAS from substantial is submission partnered and X early with later inhibitors, hemophilia potential data programs with as in with with Sanofi, in
clinical Now, been mid believe making with we programs, stage in also programs. addition great our stage early we've to our late progress and
needs is now RNAi unmet and we time pharmacological of therapeutics beyond as gout, others, now One properties common Rare the therapeutics prevalent such settings success. Disease address our exciting parts to hypertension, believe of Nash, opportunities. expansion RNAi of the potential many in the diabetes, the believe of into disease provide foundation disease story the We for amongst is
Our example. a is for program hypertension great
pressure co-administration observed dosing studies durable generally potentially the quarterly a these been blood designed has X tolerability [Indiscernible]. well greater completed pharmacology year. was to data XX. with formally cohorts an investigational tonic Phase Belcesiran, augmented known Belcesiran quarter, interim two has if of study So by during low encouraging the than in inducing persisted this XX targeting we parts the from in In doses or systolic highest doses reductions patients the millimeters study treatment XX% greater the weeks. single week eight of single the milligrams is X of is target than as which angiotensinogen through blood RAAS with diet XX of conventional We of XXX throughout week genetically two the after observed than serum Phase may observed. millimeters biannual effects In at treated in believe salt support with hour readout dose These reported for ALN-HTT of The with potential hypertension. or of second RNAi In of expected control today. once durable dosing effect later therapeutic assess XX validated either experienced profile mercury blood higher results group higher XXX of inhibitor pharmacologic in more at milligrams mercury doses pressure reduction by tolerated, regimen. of Belcesiran have antihypertensive or AGT Belcesiran and safety now Reductions pressure the
We cardio also recently program initiated X Phase our Zilebesiran. with
of on standard patients the studies the study Zilebesiran moderate first in and monotherapy KARDIA-X with Zilebesiran receiving an late In The mild plan two to of This with the currently hypertension evaluate and which to uncontrolled evaluate patients. is efficacy safety hypertension. patients KARDIA-X we in enrolling designed to care. in designed of with as XXXX, treatment safety is efficacy of add-on therapy while initiating is
and knockdown genetic of loss of n ALN-HSD mediated patient. RNAi to findings We patients. we're has X Phase Part Nash. continues that in collaboration in ALN-HSD, treatment will also which dosing with study with HSDXXBXX advancing now reducing of inflammation, Regeneron B function Nash injury transitioned on, and dosing partner in of Moving for believe Nash Enrollment hepatic fibrosis the our mimic the
a or B turn receive observed Let's profile attractive. Vir. to Phase X cohort to right considered June results of surface in presented opt more of the When ALN-HBVXX interferon program, known to in for from Hepatitis commercialize a showing HBVOX our ALN-HBVXX weeks, as to surface positive develop partnership royalties combined with to and XX study also in At reduction briefly and and as EASL alone, intend rapid and co Alnylam Vir a VIR-XXXX, meeting co-administration alpha decline with pegylated hepatitis B safety we compared milestones was be HBVOX substantial co in quite a free antigen reminder, to the antigen.
in pioneered for therapeutics painful significant great for for new made attacks and The protection. very need with our recurrent treatment treatments broad for a ALN-XDH And development to and are also RNAi in debilitating XXXX. to program address this gout intellectual scientists We CTA this preclinical progress condition. program our gout property with the file of plan condition unmet late
dominant make also we for disease our timeline. the and CTA now in autosomal Notably, representing in in with preclinical a treatment We Regeneron. small late the RNAi file continue to progress and for shift Alzheimer's beyond continue our ocular includes great efforts development amyloid on liver. many cerebral CNS our to advance We opportunities angiopathy. ALN-APP our therapeutic plan This for to ALN-APP XXXX a program
our based ALN-COV development let is that, Jeff? of Finally, COVID-XX. of our review With to This decision the effective financial treatment a treatment alternative over morning, in discontinue this in the it highly Jeff to release our to COVID-XX. program options turn announced availability we and for vaccines results. press decision our me on now for portfolio
